Lung cancer: Portrazza receives FDA nod for treatment of advanced squamous non-small cell lung cancer

The U.S. Food and Drug Administration Tuesday approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer. Lung cancer is the leading cause of cancer death in the United States, ["]